Skip to main content
. Author manuscript; available in PMC: 2022 Mar 2.
Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2020 Sep 4;106:110089. doi: 10.1016/j.pnpbp.2020.110089

Figure 1. Schematic of experimental design.

Figure 1.

A.) WT and iTat mice were assessed for PPI at baseline (Phase 1: pre-METH and pre-DOX) and matched into four groups (WT+saline, WT+METH, Tat+saline, Tat+METH; n=15/group) based on percent PPI and startle reactivity. Two days later, mice began a 25 day regimen of injections with either saline or METH. Mice were assessed again for PPI on the 23rd day of METH treatment (Phase 2: during METH and pre-DOX). The next day, a 7 day DOX treatment (85 mg/kg) was started. Mice were assessed for PPI a final time (Phase 3: post-METH and DOX) two days after completion of the DOX regimen. B.) METH was administered four times per day in an escalating manner, starting with 1 mg/kg and ending at 6 mg/kg. Injections were given for four days, followed by three days of no injections. This pattern was repeated a total of four times. C.) Participants with or without HIV and with or without a history of METH dependence were recruited for the human studies.